Richard Hafner - Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

基本信息

浏览量：134

职业迁徙

个人简介

Skills and Expertise
Infection
Tuberculosis
Mycobacterium Tuberculosis
Infectious Disease Epidemiology
Clinical Infectious Diseases
Infectious Disease Medicine
Drug Resistance
Immunology of Infectious Diseases
Trials
HIV/AIDS

研究兴趣

论文共 107 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial

Kamunkhwala Gausi,Elisa H. Ignatius,Xin Sun,Soyeon Kim,Laura Moran,Lubbe Wiesner,Florian von Groote-Bidlingmaier,Richard Hafner,Kathleen Donahue,Naadira Vanker,Susan L. Rosenkranz,Susan Swindells,Andreas H. Diacon,Eric L. Nuermberger,Kelly E. Dooley,Paolo Denti

American Journal of Respiratory and Critical Care Medicine（2021）

引用20浏览0WOS引用

Advances in Host-Directed Therapies Against Tuberculosis

Petros C. Karakousis,Richard Hafner,Maria Laura Gennaro

Advances in Host-Directed Therapies Against Tuberculosis (2021)

引用21浏览0引用

QT Effects of Bedaquiline, Delamanid, or Both in Patients with Rifampicin-Resistant Tuberculosis: a Phase 2, Open-Label, Randomised, Controlled Trial

Kelly E. Dooley,Susan L. Rosenkranz,Francesca Conradie,Laura Moran,Richard Hafner,Florian Von Groote-Bidlingmaier,Javier R. Lama,Justin Shenje,Jorge De los Rios,Kyla Comins,Joel Morganroth,Andreas H. Diacon,Yoninah S. Cramer,Kathleen Donahue,Gary Maartens

LANCET INFECTIOUS DISEASES（2021）

引用74浏览0WOS引用

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Kelly E. Dooley,Sachiko Miyahara,Florian von Groote-Bidlingmaier,Xin Sun,Richard Hafner,Susan L. Rosenkranz,Elisa H. Ignatius,Eric L. Nuermberger,Laura Moran,Kathleen Donahue,Susan Swindells,Naadira Vanker,Andreas H. Diacon

American journal of respiratory and critical care medicine（2020）

引用7浏览0WOS引用

Assessing Whether Isoniazid is Essential During the First 14 Days of Tuberculosis Therapy: a Phase 2a, Open-Label, Randomised Controlled Trial

Andreas Diacon,Sachiko Miyahara,Rodney Dawson,Xin Sun,Evelyn Hogg,Kathleen Donahue,Michael Urbanowski,Veronique De Jager,Courtney Fletcher,Richard Hafner,Susan Swindells,William Bishai

The Lancet Microbe（2020）

引用6浏览0WOS引用

Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (inhindsight): A Randomized, Open-Label Clinical Trial

American Journal of Respiratory and Critical Care Medicineno. 11 (2020): 1416-1424

引用46浏览0WOS引用

The China Tuberculosis Clinical Trials Consortium Network: a Model for International TB Clinical Trials Capacity Building

Yu-Hong Liu,Shu Chen,Jing-Tao Gao,Yao Zhang, Kimberly Booher, Xiao-Fen Ding,Wei Shu,Jian Du,Jing Bao,Richard Hafner,Carol D. Hamilton,Liang Li

Infectious Diseases of Poverty（2020）

引用2浏览0WOS引用

Therapies for Tuberculosis and AIDS: Myeloid-Derived Suppressor Cells in Focus

Anca Dorhoi,Leigh A. Kotzé,Jay A. Berzofsky,Yongjun Sui,Dmitry I. Gabrilovich,Ankita Garg,Richard Hafner,Shabaana A. Khader,Ulrich E. Schaible,Stefan H. E. Kaufmann,Gerhard Walzl,Manfred B. Lutz,Robert N. Mahon,Suzanne Ostrand‐Rosenberg,William R. Bishai,Nelita du Plessis

The Journal of clinical investigation/The journal of clinical investigationno. 6 (2020): 2789-2799

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn